[Treatment of Kaposi's disease].
Several clinical, epidemiological and immunological data support the opportunistic nature of Kaposi's disease. Although the physiopathology of the disease is unknown, its characteristics, and particularly its immunological dependence, have repercussions on treatment which must avoid making the immunological process worse, especially since the proliferation is rarely life-threatening. Recent therapeutic innovations, such as alpha interferon, have failed to bring the expected results which are disappointing in the form associated with the acquired immunodeficiency syndrome. In the classical form of the disease radiotherapy and chemotherapy provide a satisfactory improvement without any side-effect that might threaten the patient's life.
Bachelez
H
H
Service de Dermatologie clinique et Vénéréologie, Hôpital Henri Mondor, Créteil.
Revuz
J
J
D000163:Acquired Immunodeficiency Syndrome / Q000628:therapy; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D005047:Etoposide / Q000008:administration & dosage; D006801:Humans; D007372:Interferons / Q000627:therapeutic use; D012514:Sarcoma, Kaposi / Q000188:drug therapy / Q000503:physiopathology / Q000532:radiotherapy / Q000628:therapy*; D014748:Vinca Alkaloids / Q000008:administration & dosage
D014748:Vinca Alkaloids; D005047:Etoposide; D007372:Interferons
Traitement de la maladie de Kaposi.